Payment overview · 2025
General Payments
$675.62
32 reported records · 16 companies
Healthcare provider profile · identity verified
Brandon Gregory Gibson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · JOPLIN, MO · NPI 1891084943
Verified facts
What the public records show
CMS Open Payments records show Brandon Gregory Gibson, DO received $675.62 in general payments during 2025 across 32 reported records.
Aroa Biosurgery Incorporated accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $133.51 | 19.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.74 | 18.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.23 | 13.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.50 | 7.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.74 | 7.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.69 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.85 | 4.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.54 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.12 | 2.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.33 | 2.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.89 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.52 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.79 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.98 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.65 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.54 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $675.62 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.76 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.98 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.70 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.74 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.56 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.56 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 204 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 238 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
120 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
204 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
238 | 40 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1048 | 255 |
| Amlodipine Besylate | Amlodipine Besylate | 925 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 870 | 191 |
| Pantoprazole Sodium | Pantoprazole Sodium | 703 | 160 |
| Lisinopril | Lisinopril | 696 | 174 |
| Gabapentin | Gabapentin | 626 | 121 |
| Carvedilol | Carvedilol | 537 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 503 | 109 |
| Losartan Potassium | Losartan Potassium | 419 | 101 |
| Omeprazole | Omeprazole | 396 | 84 |
| Furosemide | Furosemide | 394 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 356 | 74 |
| Montelukast Sodium | Montelukast Sodium | 340 | 85 |
| Tramadol Hcl | Tramadol Hcl | 337 | 66 |
| Potassium Chloride | Potassium Chloride | 335 | 69 |
| Meloxicam | Meloxicam | 328 | 89 |
| Alprazolam | Alprazolam | 318 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 310 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 291 | 65 |
| Sertraline Hcl | Sertraline Hcl | 246 | 53 |
| Metformin Hcl | Metformin Hcl | 241 | 66 |
| Ozempic | Semaglutide | 238 | 40 |
| Eliquis | Apixaban | 228 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 55 |
| Farxiga | Dapagliflozin Propanediol | 204 | 34 |
| Allopurinol | Allopurinol | 203 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 39 |
| Lorazepam | Lorazepam | 188 | 49 |
| Trazodone Hcl | Trazodone Hcl | 186 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 51 |
| Pregabalin | Pregabalin | 178 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 52 |
| Glimepiride | Glimepiride | 169 | 41 |
| Alendronate Sodium | Alendronate Sodium | 151 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 41 |
| Simvastatin | Simvastatin | 148 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 140 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 136 | 27 |
| Azithromycin | Azithromycin | 127 | 104 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 28 |
| Memantine Hcl | Memantine Hcl | 125 | 18 |
| Finasteride | Finasteride | 124 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 28 |
| Linzess | Linaclotide | 120 | 19 |
| Jardiance | Empagliflozin | 118 | 25 |
| Atenolol | Atenolol | 115 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 26 |
| Donepezil Hcl | Donepezil Hcl | 113 | 23 |
| Spironolactone | Spironolactone | 113 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 23 |
| Cefdinir | Cefdinir | 107 | 82 |
| Doxazosin Mesylate | Doxazosin Mesylate | 107 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 31 |
| Buspirone Hcl | Buspirone Hcl | 99 | 23 |
| Celecoxib | Celecoxib | 97 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 73 |
| Mirtazapine | Mirtazapine | 88 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 13 |
| Clonazepam | Clonazepam | 81 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 30 |
| Baclofen | Baclofen | 80 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | 18 |
| Myrbetriq | Mirabegron | 76 | 13 |
| Mounjaro | Tirzepatide | 70 | 11 |
| Benazepril Hcl | Benazepril Hcl | 69 | 14 |
| Januvia | Sitagliptin Phosphate | 67 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 65 | 65 |
| Divalproex Sodium Er | Divalproex Sodium | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 16 |
| Methylprednisolone | Methylprednisolone | 64 | 54 |
| Colestipol Hcl | Colestipol Hcl | 63 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Bupropion Xl | Bupropion Hcl | 59 | 13 |
| Famotidine | Famotidine | 59 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 16 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Diazepam | Diazepam | 57 | 13 |
| Ezetimibe | Ezetimibe | 55 | 12 |
| Cephalexin | Cephalexin | 54 | 15 |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | 13 |
| Synthroid | Levothyroxine Sodium | 52 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Lovastatin | Lovastatin | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 42 |
| Estradiol | Estradiol | 50 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 50 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 28 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Prednisone | Prednisone | 44 | 22 |
| Entresto | Sacubitril/Valsartan | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 17 |
| Valacyclovir | Valacyclovir Hcl | 41 | 19 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Glipizide | Glipizide | 39 | 12 |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | 11 |
| Cartia Xt | Diltiazem Hcl | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | 22 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 23 |
| Naproxen | Naproxen | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Prolia | Denosumab | 26 | 17 |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 14 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Prevalite | Cholestyramine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Armodafinil | Armodafinil | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Daliresp | Roflumilast | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $675.62 · 32 records | Aroa Biosurgery Incorporated | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error